The pharmaceutical sector is seeing a important shift in blood sugar care with the introduction of GLP-1 transdermal devices. These revolutionary vehicles offer a potentially simple choice to subcutaneous injections for individuals dealing with diabetes mellitus type 2. By bypassing the need for